Current and potential targets for drug design in the androgen receptor pathway for prostate cancer

Research output: Contribution to journalReview article

Abstract

Introduction: Modulating the androgen axis by different agents has been one of the most successful therapeutic interventions in the field of prostate cancer therapy. Newer agents such as abiraterone and enzalutamide have been widely adapted and have contributed to an increase in the overall survival of prostate cancer patients. However, most of these patients will develop resistance to these agents and will need chemotherapy. Areas covered: In this review, this author discusses current agents which modulate the androgen axis, the mechanisms of resistance to these agents and investigative agents which are designed to bypass these mechanisms of resistance. Potential targets in the androgen axis and related biochemical pathways are, furthermore, identified. Expert opinion: Understanding the mechanism of resistance to these agents is crucial in developing third generation anti-androgen agents which can potentially contribute to the longevity of prostate cancer patients to a greater extent. Besides developing more potent agents, it is also important to formulate new strategies to resensitize patients to current anti-androgen agents by carefully sequencing chemotherapy regimens and abrogating genetic changes which are known to cause resistance to anti-androgens. Combinatorial approach with immunotherapy offers prospects which may yield better results and need to be thoroughly explored.

Original languageEnglish (US)
Pages (from-to)489-496
Number of pages8
JournalExpert Opinion on Drug Discovery
Volume13
Issue number6
DOIs
StatePublished - Jun 3 2018
Externally publishedYes

Fingerprint

Drug Design
Androgen Receptors
Androgens
Prostatic Neoplasms
Drug Therapy
Expert Testimony
Immunotherapy
Survival
Therapeutics

Keywords

  • Androgen
  • Prostate cancer
  • therapy

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Current and potential targets for drug design in the androgen receptor pathway for prostate cancer. / Guddati, Achuta Kumar.

In: Expert Opinion on Drug Discovery, Vol. 13, No. 6, 03.06.2018, p. 489-496.

Research output: Contribution to journalReview article

@article{354aa649d55244b5930252083b135757,
title = "Current and potential targets for drug design in the androgen receptor pathway for prostate cancer",
abstract = "Introduction: Modulating the androgen axis by different agents has been one of the most successful therapeutic interventions in the field of prostate cancer therapy. Newer agents such as abiraterone and enzalutamide have been widely adapted and have contributed to an increase in the overall survival of prostate cancer patients. However, most of these patients will develop resistance to these agents and will need chemotherapy. Areas covered: In this review, this author discusses current agents which modulate the androgen axis, the mechanisms of resistance to these agents and investigative agents which are designed to bypass these mechanisms of resistance. Potential targets in the androgen axis and related biochemical pathways are, furthermore, identified. Expert opinion: Understanding the mechanism of resistance to these agents is crucial in developing third generation anti-androgen agents which can potentially contribute to the longevity of prostate cancer patients to a greater extent. Besides developing more potent agents, it is also important to formulate new strategies to resensitize patients to current anti-androgen agents by carefully sequencing chemotherapy regimens and abrogating genetic changes which are known to cause resistance to anti-androgens. Combinatorial approach with immunotherapy offers prospects which may yield better results and need to be thoroughly explored.",
keywords = "Androgen, Prostate cancer, therapy",
author = "Guddati, {Achuta Kumar}",
year = "2018",
month = "6",
day = "3",
doi = "10.1080/17460441.2018.1455662",
language = "English (US)",
volume = "13",
pages = "489--496",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Current and potential targets for drug design in the androgen receptor pathway for prostate cancer

AU - Guddati, Achuta Kumar

PY - 2018/6/3

Y1 - 2018/6/3

N2 - Introduction: Modulating the androgen axis by different agents has been one of the most successful therapeutic interventions in the field of prostate cancer therapy. Newer agents such as abiraterone and enzalutamide have been widely adapted and have contributed to an increase in the overall survival of prostate cancer patients. However, most of these patients will develop resistance to these agents and will need chemotherapy. Areas covered: In this review, this author discusses current agents which modulate the androgen axis, the mechanisms of resistance to these agents and investigative agents which are designed to bypass these mechanisms of resistance. Potential targets in the androgen axis and related biochemical pathways are, furthermore, identified. Expert opinion: Understanding the mechanism of resistance to these agents is crucial in developing third generation anti-androgen agents which can potentially contribute to the longevity of prostate cancer patients to a greater extent. Besides developing more potent agents, it is also important to formulate new strategies to resensitize patients to current anti-androgen agents by carefully sequencing chemotherapy regimens and abrogating genetic changes which are known to cause resistance to anti-androgens. Combinatorial approach with immunotherapy offers prospects which may yield better results and need to be thoroughly explored.

AB - Introduction: Modulating the androgen axis by different agents has been one of the most successful therapeutic interventions in the field of prostate cancer therapy. Newer agents such as abiraterone and enzalutamide have been widely adapted and have contributed to an increase in the overall survival of prostate cancer patients. However, most of these patients will develop resistance to these agents and will need chemotherapy. Areas covered: In this review, this author discusses current agents which modulate the androgen axis, the mechanisms of resistance to these agents and investigative agents which are designed to bypass these mechanisms of resistance. Potential targets in the androgen axis and related biochemical pathways are, furthermore, identified. Expert opinion: Understanding the mechanism of resistance to these agents is crucial in developing third generation anti-androgen agents which can potentially contribute to the longevity of prostate cancer patients to a greater extent. Besides developing more potent agents, it is also important to formulate new strategies to resensitize patients to current anti-androgen agents by carefully sequencing chemotherapy regimens and abrogating genetic changes which are known to cause resistance to anti-androgens. Combinatorial approach with immunotherapy offers prospects which may yield better results and need to be thoroughly explored.

KW - Androgen

KW - Prostate cancer

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85046903575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046903575&partnerID=8YFLogxK

U2 - 10.1080/17460441.2018.1455662

DO - 10.1080/17460441.2018.1455662

M3 - Review article

VL - 13

SP - 489

EP - 496

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 6

ER -